<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477369</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1464101</org_study_id>
    <nct_id>NCT04477369</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Volunteers</brief_title>
  <official_title>An Exploratory Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202003 or DWC202004 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the differences in pharmacokinetics and safety
      characteristics between Test Drugs(DWJ1439, DWJ1464) and that of Reference Drugs(DWC202003,
      DWC202004) in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to explore the differences in pharmacokinetics and safety
      characteristics between Test Drugs(DWJ1439, DWJ1464) and that of Reference Drugs(DWC202003,
      DWC202004) in healthy adults with fasting state: Randomized, open-label, oral, single-dose,
      four-treatment, three-period, non-replicated crossover study
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: AUC0-t</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: Cmax</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Maximum plasma drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: AUC0-t</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: Cmax</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Maximum plasma drug concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: AUCinf</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from drug administration to drug elimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: Tmax</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Time to reach maximum plasma concentration following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: t1/2</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: , Cl/F</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Apparent total clearance of drug from plasma after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected ursodeoxycholic acid: Vd/F</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Apparent volume of distribution after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: AUCinf</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from drug administration to drug elimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: Tmax</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Time to reach maximum plasma concentration following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: t1/2</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: Cl/F</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Apparent total clearance of drug from plasma after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of baseline corrected/uncorrected total ursodeoxycholic acid: Vd/F</measure>
    <time_frame>0 - 72 hours after dosing</time_frame>
    <description>Apparent volume of distribution after oral administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1439</intervention_name>
    <description>300mg single dose</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1464</intervention_name>
    <description>300mg single dose</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWC202003</intervention_name>
    <description>300mg single dose</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWC202004</intervention_name>
    <description>300mg single dose</description>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers aged 19 years old to under 55.

          -  BMI 18.0≥ and ≤30 kg/m² with body mass ≥50 kg

          -  Those who have no congenital or chronic disease requiring treatment and have no
             pathological symptoms or findings as a result of medical examination.

          -  Those who have no clinically significant abnormalities in general physical
             examination, laboratory assessments and 12-lead electrocardiogram (ECG).

          -  Those who understand the requirements of the study and sign a written informed
             consent, and also accept all the restrictions imposed during the course of the study.

        Exclusion Criteria:

          -  Known history or presence of any clinically significant medical condition.

          -  Participation in a clinical drug study or bioequivalence study 6 months prior to the
             present study.

          -  Refusal to abstain from smoking or consumption of tobacco products 72 hours before
             drug administration and during each study period.

          -  Refusal to abstain from alcohol, caffeine, or other xanthines, or grapefruit
             containing food or drinks for 72 hours before drug administration and during each
             study period.

          -  Refusal to abstain from strenuous activities for 72 hours before drug administration
             and post-study visit, before and during each study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bo-Hyung Kim</last_name>
    <phone>+82-2-958-9326</phone>
    <email>bhkim98@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyung Hee University Medical Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Bo-Hyung Kim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

